Objectives: To compare the frequency of grade 3 or 4 transaminase elevations (TEs) in HIV/hepatitis C virus (HCV) co-infected patients who started a three-antiretroviral drug regimen including efavirenz or a ritonavirboosted protease inhibitor (PI/r) and the influence of pre-existing significant hepatic fibrosis or cirrhosis.
Introduction
Co-infection with hepatitis C virus (HCV) has become a major concern in the management of HIV infection. Although potent antiretroviral therapy (ART) can slow down the fibrosis progression caused by viral hepatitis, 1, 2 hepatotoxic events, such as grade 3 -4 liver enzyme elevations, acute liver failure and death, caused by antiretroviral drugs are observed more frequently in HCV/HIV co-infected patients. 3 It is known that the use of unboosted protease inhibitors (PIs) of the first generation and that of nevirapine is associated with a higher risk of transaminase and bilirubin elevations in this population. 4 -7 However, data on the liver safety of efavirenz and more recently introduced ritonavir-boosted PIs (PI/r) in HIV/HCV co-infected individuals are controversial. Currently available information on the liver toxicity related to PI/r and efavirenz is derived from both clinical trials and cohort studies. Clinical trials that have determined the liver safety of efavirenz and PI/r in co-infected patients are limited and include a low number of HIV/HCV co-infected patients. 7 -11 On the other hand, although some cohort studies have been carried out in the HIV/HCV co-infected population, there are no prospective cohort studies comparing the liver safety of efavirenz and PI/r in a single population and with the same methodology. For this reason, the frequencies of grade 3 -4 transaminase elevations (TEs) associated with the most commonly used PI/r at the moment, such as ritonavir-boosted lopinavir, atazanavir, darunavir and fosamprenavir, found in these studies cannot be compared with those reported for patients on efavirenz-based ART since they are derived from different retrospective study populations conducted with distinct methodologies. 5,6,12 -16 Therefore, prospective cohort studies comparing these antiretroviral drugs, followed by the same physician and analysed with uniform criteria, are necessary in order to determine the liver safety of efavirenz and currently used PI/r.
In addition, the information about the impact of pre-existing liver fibrosis on grade 3 -4 liver toxicity associated with efavirenz and PI/r-based ART is unclear. 14 -17 Thus, a higher frequency of grade 3-4 TEs in individuals with advanced fibrosis receiving efavirenz-based ART has been shown in one study. 17 In contrast, other reports did not find an influence of baseline significant fibrosis on the frequency of grade 3 -4 TEs related to ritonavirboosted atazanavir, darunavir and fosamprenavir. 14 -16 To elucidate this topic, data on the liver safety of efavirenz and PI/r in the subgroup of subjects with significant fibrosis and cirrhosis are required in order to select the safer antiretroviral drug options in this population.
For these reasons, we conducted this study, the objective of which was to compare the liver toxicity in HIV/HCV co-infected patients who start a three-antiretroviral drug regimen including two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus efavirenz or a PI/r, as well as the influence of the degree of pre-existing liver fibrosis.
Patients and methods

Study design and patients
All pre-treated or treatment-naive HIV/HCV co-infected patients in seven Spanish centres from January 2007 to December 2009 who started a three-antiretroviral drug regimen including two NRTIs along with efavirenz or a PI/r were included in this prospective multicentre cohort study. All patients fulfilled the following criteria: (i) older than 18 years; (ii) chronic HCV infection as confirmed by HCV antibodies in plasma, as well as a positive HCV viral load determined by PCR; and (iii) at least 1 week receiving the new antiretroviral regimen. Before treatment initiation, epidemiological data were obtained in a structured interview including self-referred alcohol consumption. Clinical visits and blood tests were scheduled at baseline, 1 month after starting the new regimen and every 3 months during the first year and every 4 -6 months afterwards. The follow-up was stopped if the patient initiated anti-HCV treatment, as well as at the moment of discontinuation of efavirenz or the PI/r due to any cause, death, or the scheduled end of follow-up (December 2010). Patients who received daily doses of ritonavir .200 mg/day, as well as those with previous hepatotoxic events, were excluded from the study.
Antiretroviral drug regimens
The use of ART was applied following recommendations of the guidelines of the Grupo Españ ol para el Estudio del SIDA (GESIDA), the U.S. Department of Health and Human Services (DHHS) and the European AIDS Clinical Society (EACS) at the time of prescription. 18 -20 The final decision on the specific drug used was made according to the attending physician. Efavirenz was administered at a dose of 600 mg/day. The daily doses of the PI/r prescribed in this study were lopinavir/ritonavir, 800/200 mg; fosamprenavir/ritonavir, 1400/100-200 mg; darunavir/ritonavir, 800-1200/100 -200 mg; atazanavir/ritonavir, 300/100 mg; and saquinavir/ ritonavir, 1500/100 mg.
Definition of liver toxicity
Prior to the study initiation, grade 3 and 4 TEs were defined according to the baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values. In detail, grade 3 TEs were considered when elevations 5 -10 times the upper level of normality (ULN) were presented in patients with normal baseline levels of ALT and AST. Grade 4 TEs were defined as ALT or AST values .10 times the ULN. In patients with elevated baseline ALT or AST levels, a 3.5-to 5-fold increase from baseline levels was considered a grade 3 TE and .5-fold elevation was considered a grade 4 TE. Grade 4 total bilirubin elevations (TBEs) were defined as increases of total bilirubin ≥5 mg/dL.
Assessment of liver fibrosis
The determination of liver fibrosis was performed according to the application of an algorithm that has been described elsewhere with some modifications.
14 Briefly, biopsies that diagnosed significant fibrosis, i.e. fibrosis extending beyond the portal tracts (F≥ 2), or cirrhosis according to the Scheuer scoring system were considered as valid if they (i) measured at least 15 mm; (ii) were not fragmented; and (iii) were obtained prior to or up to 1 year after starting the new ART. Likewise, biopsies that exclude significant fibrosis or cirrhosis were considered for determination if they were obtained within 1 year before or at any moment after treatment initiation. In patients without a valid biopsy, hepatic transient elastometry (FibroScan TM , Echosens, Paris, France) was used to diagnose or exclude significant fibrosis and cirrhosis, applying the same time scheme as used for validation of the liver biopsy. Significant fibrosis was assumed when liver stiffness values were ≥7.2 kPa, while values ≥14.6 kPa were considered as cirrhosis. 21 Finally, for those patients without liver biopsy or liver stiffness measurements, the blood biomarkers AST-to-platelet ratio index (APRI) and the Forns index were calculated. Significant fibrosis was considered in those patients presenting baseline APRI values ≥1.5, as well as those with APRI values ,1.5, but Forns index values ≥6.9.
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Statistical analysis
The sample size of the two groups was calculated based on the frequencies of grade 3 -4 TEs reported earlier for efavirenz and PI/r. Thus, estimating a frequency of grade 3-4 TEs for efavirenz of 17% 6, 12 and 5% for PI/r, 13 -16 given a ratio 3: 7 for patients receiving efavirenz to those with a PI/r to reach a statistical power of 80% with an alpha error of 5%, a minimum of 230 patients (69 receiving efavirenz and 161 a PI/r) needed to be included. The outcome variables of this study were the development of grade 3 -4 TEs and grade 4 TBEs during follow-up. Comparative analyses of TEs and TBEs were carried out between those Neukam et al.
subjects included in the efavirenz group and in the PI/r group. Additionally, we assessed the relationship between the outcome variable and the following potential predictors: age, sex, previous intravenous drug use, alcohol consumption, baseline ALT levels, baseline CD4 cell count, CDC category C, undetectable plasma HIV-RNA, HCV genotype, previous ART, type of PI/r, as well as significant fibrosis and cirrhosis at initiation of the new ART regimen.
Continuous variables were expressed as median [interquartile range (IQR)] and categorical variables as number [percentage; 95% confidence interval (CI)]. The density of incidence of grade 3-4 TEs was calculated as the number of cases per 100 person-years of the follow-up. Continuous variables were compared using the Student's t-test for normal distribution and the Mann-Whitney U-test otherwise, whereas the categorical variables were analysed by applying the x 2 test or Fisher's test, when applicable. The Wilcoxon signed rank test and the McNemar test were applied to compare repeated measurements in continuous and categorical variables, respectively. Row-by-column x 2 contingency tables were used to analyse the frequency of TEs and TBEs among the different PI/ r used in this study. Those factors that showed an association in the univariate analysis with a P,0.2, as well as those with a biologically plausible influence, were entered into a logistic regression model in order to identify independent risk factors for grade 3 -4 TEs and grade 4 TBEs. The adjusted odds ratio (AOR) and the respective 95% CI were calculated. All P values ,0.05 were considered statistically significant. The sample size of this study was calculated using Ene 3.0 (GlaxoSmithKline, S.A., Madrid, Spain). Data were analysed using the SPSS statistical software package release 19.0 (SPSS Inc., Chicago, IL, USA) and STATA 9.0 (StataCorp LP, College Station, TX, USA).
Ethical aspects
The study was designed and performed according to the Helsinki declaration and was approved by the Autonomic Committee for Clinical Studies of the Council of Andalusia (Spain). All patients gave their written informed consent before being included in the study.
Results
Characteristics of the study population
Two hundred and sixty-two patients were included in this study. A detailed description of the study population is presented in Table 1 . A total of 101 (38.5%) individuals had not received ART prior to entering into the study. Forty-one (15.6%) patients started the new ART regimen due to virological failure, 38 (14.5%) due to adverse events of the former treatment, 27 (10.3%) due to simplification and 55 (21%) for other reasons. Of the 161 patients who were receiving ART before entering in the study, 35 (21.5%) switched from a non-NRTI to a PI/r and 31 (19.2%) from a PI/r to efavirenz. Seventy-six (29%) patients received efavirenz and 186 (71%) received a PI/r. Table 2 shows the distribution of the different PI/rs and the concomitant NRTIs used during follow-up. The median follow-up (IQR) was 14.0 (6.2 -23.7) months. In 90 (34.4%) individuals the new treatment regimen was followed until the end of the study period Liver toxicity of efavirenz and protease inhibitors in HIV/HCV co-infection 2607 JAC (December 2010). Thirty-two (63%) of the subjects who were lost to follow-up during the study period completed the visit at 6 months after beginning efavirenz or PI/r-based ART. Detailed therapy outcomes are shown in Figure 1 . The assessment of pre-existing significant fibrosis and cirrhosis was possible in 236 (90.1%) and 216 (82.4%) patients, respectively. Baseline fibrosis was determined in 69 (90.8%) cases in the efavirenz group and in 167 (89.8%) cases in the PI/r group. Among those patients who received efavirenz, 46 (66.7%) presented significant fibrosis at baseline versus 113 (67.7%) subjects in the PI/r group (P ¼ 0.882). The corresponding figures for cirrhosis were 14 (21.9%) and 39 (25.7%), respectively (P ¼ 0.555). Figure 2 shows the algorithm applied for the determination of liver fibrosis at baseline.
Response to ART
In the overall population, the number of patients with undetectable plasma HIV-RNA increased from 69 (26.3%) patients at baseline to 188 (72%) at the end of follow-up (P,0.001). During the follow-up, the CD4 cell count (IQR) increased from 268 (136 -408) cells/mm 3 to 375 (234-557) cells/mm 3 (P,0.001). The corresponding figures for the patients receiving efavirenz or a PI/r are shown in Table 3 .
Liver enzyme elevations
In the overall population, episodes of grade 3 -4 TEs were observed in 20 (7.6%; 95% CI 4.7% -11.5%) patients and the density of incidence was 5.64 cases per 100 person-years. Eight (3.1%) patients presented events of hepatic decompensation during the follow-up: six patients developed ascites, one hepatic encephalopathy and one jaundice. Of these, two individuals presented decompensations of cirrhosis prior to treatment initiation. The number of patients with hepatic decompensation among those with cirrhosis at baseline was three (21.4%) in the efavirenz group and five (10.3%) in the PI/r group (P ¼ 0.29). All events within the PI/r group were observed in patients who received ritonavir-boosted lopinavir.
In the efavirenz group, 5 (6.6%; 95% CI 2.2% -14.7%) subjects developed grade 3 -4 TEs versus 15 (8.1%; 95% CI 4.6% -13%) of those treated with a PI/r (P ¼ 0.681). Episodes of grade 3 TEs were observed in 2 (2.6%; 95% CI 0.3% -9.2%) of the patients receiving efavirenz compared with 13 (7.0%; 95% CI 3.8% -11.7%) of the individuals who were treated with an antiretroviral regimen including a PI/r (P ¼0.166). Grade 4 TEs were detected in three (3.9%; 95% CI 0.8% -11.1%) cases in the efavirenz group and in two (1.1%; 95% CI 0.1% -3.8%) in the PI/r group (P¼ 0.125). EFV, efavirenz; LPV/r, ritonavir-boosted lopinavir; FPV/r, ritonavir-boosted fosamprenavir; DRV/r, ritonavir-boosted darunavir; ATV/r, ritonavirboosted atazanavir; SQV/r, ritonavir-boosted saquinavir; TDF, tenofovir; FTC, emtricitabine; 3TC, lamivudine; ABV, abacavir; ZDV, zidovudine. and 5.73 cases per 100 person-years for the use of PI/r. Table 3 shows the changes in transaminase levels during follow-up among patients receiving efavirenz or PI/r. The distribution of the cases of grade 3 -4 TEs according to the different PI/rs used is shown in Figure 3 . Among those individuals included in the PI/r group, grade 3 -4 TEs were observed in 3 (23.1%; 95% CI 5%-53.8%) of the patients who received ritonavir-boosted saquinavir versus 12 (6.9%; 95% CI 3.6% -11.8%) who did not (P ¼ 0.039). Ritonavir-boosted saquinavir was the only independent predictor of grade 3-4 TEs found in a multivariate analysis (Table 4) . Grade 4 TBEs were observed in nine (3.4%; 95% CI 1.6% -6.4%) patients: two (2.6%; 95% CI 0.3% -9.2%) receiving efavirenz and seven (3.8%; 95% CI 1.5% -7.6%) in the PI/r group (P ¼ 0.648). Two (6.5%) of these patients were treated with ritonavir-boosted atazanavir and five (3.2%) with a different PI/r (P ¼ 0.389). Previous hepatic decompensations were observed in two of those who developed grade 4 TBEs and two individuals, both receiving ritonavir-boosted lopinavir, concomitantly suffered from ascites. The changes in total bilirubin during follow-up among patients receiving efavirenz or a PI/r are shown in Table 3 . Factors associated with grade 4 TBEs in the univariate analysis are shown in Table 5 . The presence of cirrhosis at baseline was the only factor associated with grade 4 TBEs in the multivariate analysis (AOR 4.41; 95% CI 1.07 -16.03; P¼ 0.04).
Influence of pre-existing fibrosis stage on liver enzyme elevations
In the overall population, 13 (8.2%; 95% CI 4.4% -13.6%) of the 159 patients with significant fibrosis at baseline showed grade 3 -4 TEs versus 7 (9.1%; 95% CI 3.7% -17.8%) of the 77 subjects with mild to absent fibrosis (P ¼0.813). The corresponding figures for those individuals with and without cirrhosis were 6 (11.3%; 95% CI 4.3% -23%) and 14 (8.6%; 95% CI 4.8% -14%), respectively (P ¼ 0.551). In the efavirenz group, grade 3 -4 TEs were Liver stiffness ≥14.6 kPa n = 44
Fibrosis not assessed n = 26 Figure 2 . Algorithm for assessment of the liver fibrosis stage applied in this study. EFV, efavirenz; PI/r, ritonavir-boosted protease inhibitor. 
Discussion
This study shows that the frequency of grade 3-4 TEs and grade 4 TBEs associated with efavirenz is low and similar to that observed with PI/r currently used in clinical practice in HIV/HCV co-infected patients. Furthermore, no significant influence of pre-existing significant fibrosis or cirrhosis on the development of these laboratory abnormalities related to efavirenz-or PI/rbased ART was observed in this population. Several studies have assessed the severe TEs related to efavirenz and the PI/rs currently in use, 5,6,12 -16 although they are independent of each other. To our knowledge, this is the first prospective study comparing the frequency of liver toxicity associated with these antiretroviral drugs within a single cohort with a homogeneous study protocol and the same definitions of laboratory abnormalities. These conditions are essential in order to reliably compare liver toxicity associated with different antiretroviral drugs. In this context, previous studies with diverse definitions of TEs and heterogeneous populations have reported conflicting results on the liver toxicity of some antiretrovirals. Furthermore, a frequent limitation in comparing different studies is the proportion of HIV/HCV co-infected individuals included in these studies. In fact, previously published data reported a frequency of grade 3 -4 TEs of 1%-8% in HIV-infected patients without HCV co-infection receiving antiretroviral regimens including efavirenz, 6, 7, 12, 23 whereas a subanalysis of the co-infected patients within these studies showed frequencies of grade 3 -4 TEs as high as 17% 6 and 16%. 12 For these reasons, the homogeneity of our cohort, as well as the standardized methods to assess liver toxicity in a prospective study enables a highly accurate comparison between the studied antiretroviral drugs. Our study results clearly show similar frequencies of grade 3 -4 TEs and grade 4 TBEs among HCV/HIV co-infected patients receiving either efavirenz or PI/r-based ART. Therefore the results found in our study strongly support that both efavirenz and the PI/rs currently in use, such as ritonavir-boosted lopinavir, atazanavir, fosamprenavir and darunavir, can be considered similar and safe with regard to the probability of grade 3-4 TEs and grade 4 TBEs.
Although higher rates of grade 3-4 TEs have been reported previously for efavirenz, 24 a more recent study reported frequencies of grade 3 -4 TEs in the range of those observed in our study. 25 Also, greater rates of grade 3 -4 TEs were observed among patients receiving ritonavir-boosted saquinavir than in those treated with the remaining PI/r, which has been described among HIV/HCV co-infected patients. 26 Thus, in a subanalysis of the co-infected patients included in the Prometheus trial, 45% of individuals who received ritonavir-boosted saquinavir plus stavudine showed grade 3 -4 TEs. 26 However, given that the use of ritonavir-boosted saquinavir has declined considerably in recent years, a fact that is reflected in the small sample size of this subpopulation in our study, these findings are unlikely to have a relevant impact on daily clinical practice. In the case of ritonavir-boosted atazanavir, a higher, statistically nonsignificant rate of grade 4 TBEs was observed as compared with the overall population. Ritonavir-boosted atazanavir is associated with elevated total bilirubin levels, which probably contributed to this observation. 27 However, the small sample size of the ritonavir-boosted atazanavir subgroup does not allow us to draw a conclusion based on this finding. Finally, grade 3 -4 TE rates of the remaining PI/rs observed in our cohort are in agreement with the majority of the individual studies carried out in the co-infected population.
Recently the relationship between the fibrosis stage at baseline and hepatotoxicity related to ART has become a matter of debate. In a study conducted by Aranzabal et al., 17 a higher density of incidence of grade 3 -4 TEs was observed in patients with advanced fibrosis in a small population receiving efavirenzbased ART as compared with those with a lower fibrosis stage. In a subanalysis of the efavirenz-receiving population of the present study, no association between the frequency of grade 3-4 TEs and pre-existing significant fibrosis at treatment initiation was observed. Similarly, the frequency of grade 3 -4 TEs found in patients with and without pre-existing significant fibrosis who received a PI/r was similar, and in the range of the frequencies reported in recent studies carried out in HIV/HCV co-infected patients. 14 -16 Because of this, we conclude that the fibrosis stage at baseline is unlikely to influence the frequency of liver enzyme elevations caused by efavirenz or the currently prescribed PI/rs in co-infected individuals.
HIV-infected patients with HCV co-infection are susceptible to developing complications due to end-stage liver disease. Neukam et al. Liver toxicity of efavirenz and protease inhibitors in HIV/HCV co-infection 2611 JAC Pharmacokinetic alterations resulting from hepatic liver function impairment caused by cirrhosis may lead to overexposure to antiretroviral drugs, especially in the case of efavirenz. 29 However, information about the management of HIV/HCV co-infected patients with cirrhosis is scarce. In fact, recently the FDA declared in an amendment that the pharmacokinetics of efavirenz has not been adequately studied in patients with hepatic impairment and therefore caution should be exercised in administering efavirenz to these patients. 30 Thus the elaboration of safety profiles for antiretroviral drugs, especially for efavirenz, is of special concern in these patients in order to improve the use of ART in cirrhotics in clinical practice. In the present study, a trend, however statistically non-significant, toward an influence of cirrhosis at baseline on the development of grade 3 -4 TEs was observed in the efavirenz group. This was not the case in those patients receiving a PI/r-based ART. Therefore, in our opinion, due to the low number of patients with cirrhosis and receiving efavirenz in our study, larger studies are needed in order to assess this topic.
This study has some limitations. First, the sample size of patients taking a PI/r in this study was low, especially in the case of the newer drugs, such as ritonavir-boosted darunavir, as well as drugs that are becoming obsolete in current clinical practice, such as saquinavir. Nevertheless, the frequency of grade 3 -4 TEs found in our study was similar to those observed in other cohort studies individually analysing these antiretroviral drugs. 13 -16 Furthermore, one-fourth of the patients were lost to follow-up. However, the majority of these patients were lost to follow-up 6 months after starting the antiretroviral regimen. Given that most hepatotoxic events take place in the first few months after beginning ART, 31 the period of observation of our study was long enough to detect the majority of liver events in the study population. Finally, this was not a randomized clinical trial. The observational design of the study could be associated with selection biases and unbalanced inclusion of patients in either treatment group. Although we cannot exclude these biases, the differences in the baseline characteristics among both groups are observed in parameters that have no impact on the development of severe TEs. Thus the selection of drugs for individual patients might not have influenced the study results.
In conclusion, the frequency of grade 3 -4 TEs is low in HIV/HCV co-infected patients receiving efavirenz and similar to that observed in currently used PI/rs. Assuming adequate pharmacovigilance, these antiretroviral drugs can be regarded as generally safe with regard to liver toxicity. Additionally, baseline significant fibrosis or cirrhosis does not impact on the development of grade 3 -4 TEs associated with the use of PI/rs. Likewise, there is no influence of significant fibrosis on the frequency of grade 3 -4 TEs in patients receiving efavirenz, whereas the role of cirrhosis in this setting remains dubious. Neukam et al.
